Description
The abstract mentions targeting genes significant for early- and late-onset AD risk factors like APOE4, but doesn’t specify which genes or the rationale for prioritization. This specificity is essential for clinical translation of gene editing approaches.
Gap type: open_question Source paper: CRISPR/Cas9 Gene Editing: A Novel Approach Towards Alzheimer’s Disease Treatment. (2024, CNS & neurological disorders drug targets, PMID:38716549)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:46.659269+00:00”, “resolution_summary”: “Resolved by hypothesis h-c410043ac4: Antisense Oligonucleotide-Mediated APOE4 Haploinsufficiency. Supporting evidence includes debate sess_SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1_task_9aae8fc5.”, “match_counts”: {“hypothesis_matches”: 4, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-c410043ac4”, “title”: “Antisense Oligonucleotide-Mediated APOE4 Haploinsufficiency”, “score”: 0.231, “reason”: “17 token overlaps; entity overlap: apoe4”, “analysis_id”: “SDA-2026-04-02-gap-apoe4-targeting”, “target_gene”: “APOE”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.72, “confidence_score”: 0.75, “status”: “proposed”, “pubmed_evidence_ids”: [“25999527”, “33230312”, “clinical-aso-studies”, “germline-knockout-studies”]}, {“id”: “h-15336069”, “title”: “APOE Isoform Conversion Therapy”, “score”: 0.224, “reason”: “20 token overlaps; entity overlap: crispr”, “analysis_id”: “sda-2026-04-01-gap-auto-fd6b1635d9”, “target_gene”: “APOE”, “target_pathway”: “CRISPR base editing / APOE allele conversion”, “disease”: “neurodegeneration”, “composite_score”: 0.717666, “confidence_score”: 0.45, “status”: “proposed”, “pubmed_evidence_ids”: [“23571587”, “29566236”, “33649586”, “34261473”, “34731344”]}, {“id”: “h-42f50a4a”, “title”: “Prime Editing Precision Correction of APOE4 to APOE3 in Microglia”, “score”: 0.221, “reason”: “17 token overlaps; entity overlap: apoe4”, “analysis_id”: “SDA-2026-04-03-gap-crispr-neurodegeneration-20260402”, “target_gene”: “APOE”, “target_pathway”: “APOE-mediated cholesterol/lipid transport”, “disease”: “neurodegeneration”, “composite_score”: 0.826767, “confidence_score”: 0.7, “status”: “promoted”, “pubmed_evidence_ids”: [“39642875”, “40639927”, “41276911”, “41288387”, “41338186”]}, {“id”: “h-641ea3f1a7”, “title”: “H3: APOE4 Impairs Cholesterol Trafficking, Triggering Astrocyte Senescence”, “score”: 0.221, “reason”: “15 token overlaps; entity overlap: apoe4”, “analysis_id”: “SDA-2026-04-06-gap-debate-20260406-062101-5d7b9dc0”, “target_gene”: “ABCA1/ABCG1; LXR (NR1H3)”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.72, “confidence_score”: 0.72, “status”: “proposed”, “pubmed_evidence_ids”: [“16260638”, “23658199”, “25104894”, “30258072”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1_task_9aae8fc5”, “title”: “The abstract identifies APOE4 association with increased TDP-43 pathology but the mechanistic link is unexplained. This connection could reveal novel therapeutic targets since APOE4 is the strongest genetic risk factor for AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.577, “reason”: “11 token overlaps; entity overlap: apoe4, pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1”, “quality_score”: 0.61, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-193244-89904941_20260416-035819”, “title”: “The abstract identifies APOE4’s primary effect on oligodendrocyte cholesterol metabolism but doesn’t explain the mechanistic pathway. Understanding this mechanism is critical for developing targeted therapeutics that address the root cause rather than downstream effects.\n\nGap type: unexplained_observation\nSource paper: APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022, Nature, PMID:34788101)”, “score”: 0.469, “reason”: “8 token overlaps; entity overlap: apoe4, pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-193244-89904941”, “quality_score”: 0.69, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-173045-28238f1f”, “title”: “The study identifies KCNJ2 as a therapeutic target through CRISPR screening but doesn’t explain the mechanistic pathway by which this mechanosensory channel inhibition reduces neuronal death and proteinopathy. Understanding this mechanism is critical for rational drug development and predicting off-target effects.\n\nGap type: unexplained_observation\nSource paper: KCNJ2 inhibition mitigates mechanical injury in a human brain organoid model of traumatic brain injury. (2024, Cell stem cell, PMID:385”, “score”: 0.466, “reason”: “8 token overlaps; entity overlap: crispr, pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-173045-28238f1f”, “quality_score”: 0.71, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-041445-ce0abc1e_task_73907230”, “title”: “The abstract states that AQP4 ‘is part of the pathogenesis’ of CNS disorders and shows ‘notable variability’ in these conditions, but the precise causal mechanisms linking AQP4 alterations to disease development remain unexplained. Understanding these mechanisms is critical for developing AQP4-targeted therapeutics.\n\nGap type: unexplained_observation\nSource paper: Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders. (2023, Neurobiol Dis, PMID:36796590)”, “score”: 0.427, “reason”: “7 token overlaps; entity overlap: cns, pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-041445-ce0abc1e”, “quality_score”: 0.757, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-184126-b2c3e2e8”, “title”: “This study shows APOE4 carriers have enhanced beneficial innate immune responses, directly contradicting the established view of APOE4 as purely detrimental in neurodegeneration. This paradox challenges fundamental assumptions about APOE4’s role in AD pathogenesis.\n\nGap type: contradiction\nSource paper: APOE genotype-specific differences in the innate immune response (2021, JAMA Neurology, PMID:33432245)”, “score”: 0.415, “reason”: “6 token overlaps; entity overlap: apoe4, pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-184126-b2c3e2e8”, “quality_score”: 0.6, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}